These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35080624)

  • 21. Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials.
    Silva-Cardoso J; Sheikh O; Nashawi M; Pham S; Gallegos KM; Dinkha LR; Chilton RJ
    J Diabetes; 2020 Apr; 12(4):279-293. PubMed ID: 31688975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients.
    Kubica J; Kubica A; Grzelakowska K; Stolarek W; Grąbczewska Z; Michalski P; Niezgoda P; Bartuś S; Budaj A; Dąbrowski M; Drożdż J; Gellert R; Jaguszewski MJ; Jankowski P; Legutko J; Lesiak M; Leszek P; Małyszko J; Mitkowski P; Nessler J; Pawlaczyk K; Siller-Matula J; Stompór T; Wolnik B; Navarese EP
    Cardiol J; 2023; 30(1):143-149. PubMed ID: 34708866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure.
    Karangelis D; Mazer CD; Stakos D; Tzifa A; Loggos S; Verma S; Mitropoulos F
    Curr Pharm Des; 2021; 27(8):1051-1060. PubMed ID: 33143620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?
    Voorrips SN; Saucedo-Orozco H; Sánchez-Aguilera PI; De Boer RA; Van der Meer P; Westenbrink BD
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors.
    Prandi FR; Barone L; Lecis D; Belli M; Sergi D; Milite M; Lerakis S; Romeo F; Barillà F
    Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sodium-glucose cotransporter 2 inhibitor ameliorates high fat diet-induced hypothalamic-pituitary-ovarian axis disorders.
    Chen X; Huang L; Cui L; Xiao Z; Xiong X; Chen C
    J Physiol; 2022 Nov; 600(21):4549-4568. PubMed ID: 36048516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors.
    Dabravolski SA; Zhuravlev AD; Kartuesov AG; Borisov EE; Sukhorukov VN; Orekhov AN
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Seidu S; Kunutsor SK; Topsever P; Khunti K
    Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
    Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Cardiac Protection.
    Wu VC; Li YR; Wang CY
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
    Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
    J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
    Lan NSR; Fegan PG; Yeap BB; Dwivedi G
    ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic Interventions of Novel SGLT2 Inhibitors Against Metabolic Disorders: Transforming the Association into Perspectives.
    Irshad K; Akash MSH; Rehman K; Sharif H
    Endocr Metab Immune Disord Drug Targets; 2021; 21(12):2169-2180. PubMed ID: 34139987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SGLT-2 inhibitors in diabetes: a focus on renoprotection.
    Gonzalez DE; Foresto RD; Ribeiro AB
    Rev Assoc Med Bras (1992); 2020 Jan; 66Suppl 1(Suppl 1):s17-s24. PubMed ID: 31939531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
    Mima A
    J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SGLT2 Inhibitors and Their Antiarrhythmic Properties.
    Kolesnik E; Scherr D; Rohrer U; Benedikt M; Manninger M; Sourij H; von Lewinski D
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis.
    Zhang XL; Zhu QQ; Chen YH; Li XL; Chen F; Huang JA; Xu B
    J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29353233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.